Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 870-877

  Edavana, Vineetha Koroth ^a   Dhakal, Ishwori B ^a   Williams, Suzanne ^a   Penney, Rosalind ^a,b   Boysen, Gunnar ^b   Yao Borengasser, Aiwei ^a   Kadlubar, Susan ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Department of Biostatistics   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANASTROZOLE N GLUCURONIDE; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A4; HECOGENIN; LAMOTRIGINE; LAMOTRIGINE N2 GLUCURONIDE; MESSENGER RNA; RECOMBINANT ENZYME; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A4; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UGT1A4 GENE;

ANTICONVULSANTS; AROMATASE INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; NITRILES; POLYMORPHISM, SINGLE NUCLEOTIDE; SAPOGENINS; TRIAZINES; TRIAZOLES;

EID: 84875837822     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048157     Document Type: Article

References (48)

1. Anderson WF, Chatterjee N, Ershler WB, and Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27-36.
2. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, and Kamataki T (1998) UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9:845-847.
3. Antoniou T and Tseng AL (2005) Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44:111-145.
4. Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, and Guillemette C (2009) A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics 19:945-954.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, and Col NF (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937-947.
7. Chouinard S, Tessier M, Vernouillet G, Gauthier S, Labrie F, Barbier O, and Bélanger A (2006) Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol 69: 908-920.
8. Cuzick J (2003) Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96-103; discussion 264-106.
9. Dowsett M, Cuzick J, Howell A, and Jackson I; ATAC Trialists' Group (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 85:317-324.
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717.
11. Edavana VK, Dhakal IB, Yu X, Williams S, and Kadlubar S (2012) Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics. Drug Metab Dispos 40:1210-1215.
12. Ehmer U, Vogel A, Schütte JK, Krone B, Manns MP, and Strassburg CP (2004) Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39:970-977.
13. Eisen A, Trudeau M, Shelley W, Messersmith H, and Pritchard KI (2008) Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 34:157-174.
14. Erichsen TJ, Ehmer U, Kalthoff S, Lankisch TO, Müller TM, Munzel PA, Manns MP, and Strassburg CP (2008) Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol 230:252-260.
15. Erickson-Ridout KK, Sun D, and Lazarus P (2012) Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms. Pharmacogenet Genomics 22:561-576.
16. Erickson-Ridout KK, Zhu J, and Lazarus P (2011) Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet Genomics 21:539-551.
17. Fabian CJ (2007) The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract 61:2051-2063.
18. Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Di Cosimo S, Ruggeri EM, Milella M, and Ciccarese M, et al. (2006) Second- and third-generation aromatase inhibitors as firstline endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 94:1789-1796.
19. Figueroa JD, Malats N, García-Closas M, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, and Lan Q, et al. (2008) Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 29:1955-1962.
20. Guillemette C, Millikan RC, Newman B, and Housman DE (2000a) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60:950-956.
21. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000b) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
22. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, and Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95:1-8.
23. Innocenti F, Iyer L, Ramírez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692.
24. Jakoby WB and Ziegler DM (1990) The enzymes of detoxication. J Biol Chem 265: 20715-20718.
25. Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, Shahverdi K, Ward BA, Ogburn E, and Ratain MJ, et al. (2010) In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 70:854-869.
26. Lankisch TO, Vogel A, Eilermann S, Fiebeler A, Krone B, Barut A, Manns MP, and Strassburg CP (2005) Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 67:1732-1739.
27. Lazarus P and Sun D (2010) Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev 42:182-194.
28. Lewis S (2007) Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 153:182-188.
29. Ménard V, Girard H, Harvey M, Pérusse L, and Guillemette C (2009) Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat 30: 677-687.
30. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, and Schwab M, et al.; German Tamoxifen and AI Clinicians Group (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717.
31. Nakajima M and Yokoi T (2005) Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 20:227-235.
32. Needleman SJ and Tobias JS (2008) Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer. Expert Rev Anticancer Ther 8:1871-1881.
33. Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, Ozawa S, Kawamoto M, Kamatani N, and Shirao K, et al. (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20:144-151.
34. Sanford M and Plosker GL (2008) Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs 68:1319-1340.
35. Schmittgen TD and Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108.
36. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, and Wieland E (2001) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027-1034.
37. Simpson ER (2003) Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86: 225-230.
38. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
39. Strassburg CP, Oldhafer K, Manns MP, and Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
40. Strassburg CP, Vogel A, Kneip S, Tukey RH, and Manns MP (2002) Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50:851-856.
41. Turesky RJ, Lang NP, Butler MA, Teitel CH, and Kadlubar FF (1991) Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 12:1839-1845.
42. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
43. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, and Strassburg CP (2001) Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 121:1136-1144.
44. Wiener D, Fang JL, Dossett N, and Lazarus P (2004) Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190-1196.
45. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
46. Wysowski DK, Honig SF, and Beitz J (2002) Uterine sarcoma associated with tamoxifen use. N Engl J Med 346:1832-1833.
47. Zhou J, Argikar UA, and Remmel RP (2011) Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics 12:1671-1679.
48. Zhou J, Tracy TS, and Remmel RP (2010) Glucuronidation of dihydrotestosterone and transandrosterone by recombinant UDP- glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38:431-440.